Journal
BRAIN
Volume 127, Issue -, Pages 1693-1705Publisher
OXFORD UNIV PRESS
DOI: 10.1093/brain/awh198
Keywords
biomarkers; Parkinson's disease; diagnosis
Categories
Funding
- Medical Research Council [G0001067] Funding Source: researchfish
- MRC [G0001067] Funding Source: UKRI
- Medical Research Council [G0001067] Funding Source: Medline
Ask authors/readers for more resources
Biomarkers are characteristics that can be measured as an indicator of a normal biological process, and they have special relevance in Parkinson's disease. Parkinson's disease is a chronic neurodegenerative disorder that is difficult to study, given the site of pathology and because the resultant clinical phenotype fluctuates over time. We currently have no definitive diagnostic test, and thus for the clinician there is hope that biomarkers will help diagnose symptomatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of new treatments, such as neuroprotective therapies, and help stratify this heterogeneous disease. No biomarker is likely to fulfil all these functions, so we need to know how each has been validated in order to understand their uses and limitations, and be aware of potential pitfalls. In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available